Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab with Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
NCT05978609Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in biliary tract cancer (BTC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective Response Rate at 1 year. Started Jul 2023; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05978609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978609.